CoChat

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma

Open access
von Felden, Johann, Craig, Amanda J., Garcia-Lezana, Teresa, Labgaa, Ismail, Haber, Philipp K., D’Avola, Delia, Asgharpour, Amon, Dieterich, Douglas, Bonaccorso, Antoinette, Torres-Martin, Miguel, Sia, Daniela, Sung, Max W., Tabrizian, Parissa, Schwartz, Myron, Llovet, Josep M., Villanueva, Augusto · 2021 · Oncogene
Cited by 136

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Little is known about the mutational landscape of advanced hepatocellular carcinoma (HCC), and predictive biomarkers of response to systemic therapies are lacking. We aimed to describe the mutational landscape of advanced HCC and to identify predictors of primary resistance to systemic therapies using circulating tumor DNA (ctDNA). We prospectively enrolled 121 patients between October 2015 and January 2019. We performed targeted ultra-deep sequencing of 25 genes and Digital Droplet PCR of TERT promoter, including sequential samples throughout treatment. Primary endpoint was progression-free survival (PFS) stratified by mutation profiles in ctDNA. Secondary endpoints were overall survival and objective response rate. The most frequent mutations in ctDNA of advanced HCC were TERT promoter (51%), TP53 (32%), CTNNB1 (17%), PTEN (8%), AXIN1, ARID2, KMT2D , and TSC2 (each 6%). TP53 and CTNNB1 mutations were mutually exclusive. Patients with mutations in the PI3K/MTOR pathway had significantly shorter PFS than those without these mutations after tyrosine kinase inhibitors (2.1 vs 3.7 months, p < 0.001), but not after immune checkpoint inhibition (CPI). WNT pathway mutations were not associated with PFS, overall survival, or objective response after CPI. Serial profiling of ctDNA in a subset correlated with treatment response. Mutation profiling of ctDNA in advanced HCC shows similar mutation frequencies for known HCC drivers compared to early stages and identifies predictive biomarkers of response to systemic therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41388-020-01519-1

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 136

Metadata

Authors
von Felden, J., Craig, A. J., Garcia-Lezana, T., Labgaa, I., Haber, P. K., D’Avola, D., Asgharpour, A., Dieterich, D., Bonaccorso, A., Torres-Martin, M., Sia, D., Sung, M. W., Tabrizian, P., Schwartz, M., Llovet, J. M., & Villanueva, A.
Venue
Oncogene
Published
2020-10-23
Volume
40
Issue
1
Pages
140-151
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W3093530736
Cited by
136
References
17
FWCI
9.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. https://app.cochat.ai/papers/10.1038/s41388-020-01519-1
The paper
von Felden, J., Craig, A. J., Garcia-Lezana, T., Labgaa, I., Haber, P. K., D’Avola, D., Asgharpour, A., Dieterich, D., Bonaccorso, A., Torres-Martin, M., Sia, D., Sung, M. W., Tabrizian, P., Schwartz, M., Llovet, J. M., & Villanueva, A. (2021). Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. Oncogene. https://doi.org/10.1038/s41388-020-01519-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.